Retatrutide: all 32 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are OverweightRecruitingNCT07467447Phase 2
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)RecruitingNCT07165028Phase 3
• A Study of LY3437943 in Participants Who Have Obesity or Are OverweightCompletedNCT04881760Phase 2Results posted
• A Study of LY3437943 in Participants With Type 2 DiabetesCompletedNCT04867785Phase 2Results posted
• A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightActive, not recruitingNCT07357415Phase 3
• A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightActive, not recruitingNCT07232719Phase 3
• A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainActive, not recruitingNCT07035093Phase 3
• A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes MellitusActive, not recruitingNCT06982859Phase 1
• A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to HypoglycemiaCompletedNCT06982846Phase 1
• A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With ObesityActive, not recruitingNCT06859268Phase 3
• To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy ParticipantsCompletedNCT06808802Phase 1
• A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityActive, not recruitingNCT06662383Phase 3
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)Active, not recruitingNCT06383390Phase 3
• Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)CompletedNCT06354660Phase 3
• A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943CompletedNCT06313528Phase 1
• Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)Active, not recruitingNCT06297603Phase 3
• Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)Active, not recruitingNCT06260722Phase 3
• A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or ObeseCompletedNCT06039826Phase 1
• A Study of LY3437943 in Healthy Participants With a High Body Mass IndexCompletedNCT05959096Phase 1
• A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesCompletedNCT05936151Phase 2
• A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the KneeCompletedNCT05931367Phase 3
• A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightCompletedNCT05929079Phase 3
• A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightCompletedNCT05929066Phase 3
• A Study of LY3437943 in Participants With Impaired and Normal Liver FunctionCompletedNCT05916560Phase 1
• A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseCompletedNCT05882045Phase 3
• A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male ParticipantsCompletedNCT05757531Phase 1
• A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal FunctionCompletedNCT05611957Phase 1
• A Study of LY3437943 in Chinese Participants With Obesity Or OverweightCompletedNCT05548231Phase 1
• A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese ParticipantsCompletedNCT05445232Phase 1
• A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)CompletedNCT04823208Phase 1
• A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)CompletedNCT04143802Phase 1
• A Safety Study of LY3437943 Given as a Single Injection in Healthy ParticipantsCompletedNCT03841630Phase 1

← Retatrutide overview